INTRODUCTION This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the 'Kreuth IV' meeting in May 2016. AIM The objective of the meeting was for experts in the field of haemophilia from across Europe to draft resolutions regarding current issues relating to the treatment of haemophilia. RESULTS Hospita...

Sir Haemophilia rarely presents with severe visceral haemorrhage in the first week of life. A 15 hour old boy presented with haemorrhagic shock and coagulopathy. He was diagnosed with liver haemorrhage and severe haemophilia A. His younger brother, diagnosed with haemophilia at birth, presented with shock due to liver haemorrhage at 79 hours.

BACKGROUND In India, genetic counselling services are largely unavailable. The question of whether awareness of the hereditary nature of the disorder leads to modified family size in affected families remains unanswered. The objective of this study was to determine whether family history of haemophilia resulted in modification of family size in families reporting haemophilia in the State of Mah...

To describe the study design, procedures and baseline characteristics of the Haemophilia Utilization Group Study - Part Va (HUGS Va), a US multi-center observational study evaluating the cost of care and burden of illness in persons with factor VIII deficiency. Patients with factor VIII level ≤ 30%, age 2-64 years, receiving treatment at one of six federally supported haemophilia treatment cent...

UNLABELLED Treatment of elderly patients with haemophilia is an upcoming challenge in haemophilia care. We included patients with haemophilia A older than 60 years of age, who visited our haemophilia centre between 2006 and 2008. We conducted a retrospective study focussing on the patients' co-morbidities as well as changes in their bleeding patterns between 2003 and 2008. RESULTS There is a ...

SUMMARY Life expectancy for haemophilia has increased significantly in many countries. This represents a major success of the improved safety of therapeutic materials to treat haemophilia and of improved quality of care. This improved longevity will generate a population of older individuals with haemophilia with complex medical problems associated with age and managing such clinical issues is ...

INTRODUCTION Canine models of severe haemophilia resemble their human equivalents both regarding clinical bleeding phenotype and response to treatment. Therefore pre-clinical studies in haemophilia dogs have allowed researchers to make valuable translational predictions regarding the potency and efficacy of new anti-haemophilia drugs (AHDs) in humans. To refine in vivo experiments and reduce nu...

The UKHCDO inhibitor guidelines address the diagnosis and management of patients with haemophilia A, haemophilia B and acquired haemophilia. Recommendations are based on best current practice as reflected in the published evidence base. Many current treatment strategies are based on uncontrolled observations highlighting the need for well designed controlled studies.